雷替曲塞联合奥沙利铂治疗晚期结直肠癌的临床疗效观察  

The Efficacy of the Combined Raltitrexed Plus Oxaliplatin and in the Treatment of Senile Advanced Colorectal Carcinoma

作　　者：朱大高[1] 王辉[1] 

机构地区：[1]安徽省铜陵市人民医院,安徽铜陵244000

出　　处：《中国医学创新》2015年第7期51-53,共3页Medical Innovation of China

摘　　要：目的:探讨雷替曲塞联合奥沙利铂治疗晚期结直肠癌患者的临床疗效。方法:39例老年晚期大肠癌患者随机分为两组,治疗组20例,给予雷替曲塞联合奥沙利铂方案,每3周重复1次。对照组19例,予以替吉奥联合奥沙利铂方案,每3周重复1次。结果:治疗组与对照组有效率(RR)分别为60.00%与26.32%;中位疾病进展时间(TTP)分别为8.1个月与4.9个月,两组疗效比较,差异有统计学意义(P<0.05)。治疗组不良反应粒细胞减少及转氨酶增高例数较对照组多,治疗组呕吐患者明显少于对照组,比较差异有统计学意义(P<0.05)。结论:应用雷替曲塞联合奥沙利铂方案治疗老年晚期结直肠癌有一定的疗效。Objective： To observe the efficacy of the combined raltitrexed plus oxalplatin in the treatment of senile advanced colorectal carcinoma.Method： Thirty-nine advanced colorectal cancer patients were divided into two groups. The treatment group （n=20） was administered intravenously raltitrexed plus oxaliplatin regimen. The control group （n=19） was administered S1 plus Oxaliplatin regimen.Result： All the patients in the treatment group and control group were evaluated. Effective rate of the treatment group and control group was 60.00% and 26.32%, respectively. Median TTP was 8.1 and 4.9 months, respectively. The significant statistical difference was found in the short-term efficacies of the two groups （P〈0.05）. Adverse reactions compared to the elevated transaminase enzymes of the treatment group was higher than that of the control group. There were more patients who reduced neutropenia in the treatment group （P〈0.05）. There were more patients who developed vomiting in the control group （P〈0.05）.Conclusion： The raltitrexed plus oxaliplatin regimen is effective and safe in senile patients with advanced colorectal carcinoma, which is worthy of clinical popularization and application.

关 键 词：雷替曲塞 奥沙利铂 晚期结直肠癌 

分 类 号：R735.34[医药卫生—肿瘤]